PMID-20080680 – PNC-27 Kills Cancer Cells via Membrane HDM-2 Binding
Sookraj KA, Bowne WB, Adler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A. 2010;107(5):1918-1923.
Quick Reference
| Property | Value |
|---|---|
| PMID | 20080680 |
| DOI | 10.1073/pnas.0909904107 |
| Year | 2010 |
| Journal | Proceedings of the National Academy of Sciences (PNAS) |
| Study Type | In vitro |
| Evidence Level | V |
| Sample | Multiple cancer and normal cell lines |
| Peptide(s) Studied | PNC-27 |
Key Findings
- PNC-27 adopts an alpha-helical conformation that mimics the p53 HDM-2-binding domain
- The peptide selectively binds to HDM-2 expressed on cancer cell membranes but not normal cell membranes
- Binding of PNC-27 to membrane-associated HDM-2 induces membrane pore formation and cell lysis (membranolysis)
- Cancer cells express HDM-2 on their plasma membranes, while normal cells do not — this is the basis for selectivity
- Cell killing occurs by necrosis (membrane disruption), not apoptosis
Study Design
In vitro study using multiple cancer cell lines (breast MDA-MB-468, pancreatic PANC-1, melanoma A375) and normal cell lines. Fluorescence microscopy, co-immunoprecipitation, and confocal imaging used to demonstrate PNC-27/HDM-2 membrane co-localization. LDH release assays confirmed necrotic cell death. Structural analysis by circular dichroism confirmed alpha-helical conformation.
Limitations
- In vitro only — no animal or human data
- Mechanism of HDM-2 membrane translocation in cancer cells not fully elucidated
- Limited cancer cell line panel tested
- Pharmacokinetic and stability properties of the peptide not addressed
Clinical Relevance
This foundational PNAS paper established the mechanism by which PNC-27 selectively kills cancer cells: targeting membrane-associated HDM-2 that is uniquely expressed on cancer cell surfaces. This represents a novel anticancer mechanism ("poptosis" or peptide-induced transmembrane pore formation) distinct from conventional apoptosis-based therapies. The selectivity for cancer over normal cells is highly promising for therapeutic development.
Related
#research #in-vitro #PNC-27 #evidence-level-V #cancer-therapeutic